Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01

    • IGF2BP1 Drives Macrophage Glycolysis and Fibrosis via THBS1

    2026-04-28

    IGF2BP1 Drives Macrophage Glycolytic Activation and Fibrotic Phenotype via THBS1 Stabilization in Pulmonary Fibrosis

    Study Background and Research Question

    Pulmonary fibrosis (PF) is a progressive disorder marked by excessive extracellular matrix (ECM) deposition and fibroblast proliferation, leading to irreversible lung function decline. Macrophages, particularly the M2-polarized subset, play a pivotal role in orchestrating both inflammatory responses and fibrogenesis through cytokine release and metabolic modulation. Emerging evidence implicates metabolic reprogramming, especially augmented glycolysis, as a driver in fibrotic tissue remodeling. However, the molecular mechanisms linking macrophage activation, glycolytic metabolism, and fibrotic progression remain incompletely understood. N6-methyladenosine (m6A) RNA modification, a reversible epigenetic process, has recently been associated with disease states including PF, but the specific contribution of m6A readers in macrophage-driven fibrosis had not been fully elucidated. The current study addresses whether and how the m6A reader protein IGF2BP1 modulates PF development via regulation of macrophage phenotype and metabolism (reference).

    Key Innovation from the Reference Study

    The central innovation of this research lies in identifying a novel IGF2BP1/THBS1/TLR4 signaling axis that facilitates pulmonary fibrosis by stabilizing THBS1 mRNA in an m6A-dependent manner. IGF2BP1, an m6A reader protein, was shown to be overexpressed in macrophages during the fibrotic process. The study uniquely demonstrates that IGF2BP1 directly binds to and stabilizes thrombospondin-1 (THBS1) mRNA, thereby promoting macrophage glycolysis and M2 polarization, both of which are closely linked to fibrogenic activity. This mechanistic insight bridges the epitranscriptomic regulation of metabolic and phenotypic shifts in macrophages, offering new angles for therapeutic intervention in PF (reference).

    Methods and Experimental Design Insights

    The authors employed a combination of in vivo and in vitro approaches to dissect the role of IGF2BP1 in PF:

    • Animal Model: Bleomycin-induced PF in mice was used to recapitulate fibrotic lung pathology.
    • Genetic Manipulation: IGF2BP1 knockdown was achieved in macrophages, with subsequent assessment of lung histopathology, fibrosis markers, and inflammatory cell infiltration.
    • Molecular Analyses: Expression levels of fibrogenic and inflammatory markers (TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, CD163, IL-6, IL-1β, TIMP1) were quantified in both lung tissue and cultured embryonic lung fibroblasts (ELFs).
    • mRNA Interactions: RNA immunoprecipitation and m6A mapping were used to demonstrate IGF2BP1 binding and stabilization of THBS1 mRNA.
    • Functional Rescue Experiments: Overexpression of THBS1 and TLR4 was used to test their capacity to restore M2 polarization and glycolytic activity following IGF2BP1 knockdown.
    • Metabolic Assays: Glycolytic flux was assessed by measuring lactate/glucose metabolism and ATP production, alongside the expression of glycolysis-related genes (HK2, LDHA, PKM2).

    This multi-layered experimental design allowed for mechanistic dissection at molecular, cellular, and tissue levels, directly linking epitranscriptomic regulation with macrophage-driven fibrotic pathology (reference).

    Protocol Parameters

    • assay | Bleomycin-induced lung fibrosis | 2–4 mg/kg (mouse) | Applicability: In vivo fibrosis modeling | Rationale: Recapitulates human PF histopathology | source: paper
    • assay | IGF2BP1 knockdown | siRNA or shRNA (dose per protocol) | Applicability: Macrophage-specific genetic modulation | Rationale: Dissects gene function in PF | source: paper
    • assay | Macrophage M2 polarization | IL-4/IL-13 (10–20 ng/mL) | Applicability: In vitro polarization models | Rationale: Standard for inducing M2 phenotype | source: workflow_recommendation
    • assay | Glycolysis assessment | Lactate & glucose quantification, ATP assay | Applicability: Macrophage metabolic profiling | Rationale: Links metabolism to functional phenotype | source: paper
    • assay | M-CSF-driven macrophage differentiation | 10–100 ng/mL M-CSF | Applicability: Generation of primary macrophages | Rationale: Essential for macrophage survival and proliferation | source: workflow_recommendation

    Core Findings and Why They Matter

    Key observations from this study include:

    • IGF2BP1 Expression: Significantly elevated in macrophages within fibrotic lungs, and its knockdown reduced both macrophage and fibroblast profibrotic markers, as well as overall lung fibrosis severity (reference).
    • THBS1 as a Direct Target: IGF2BP1 binds to and stabilizes THBS1 mRNA in an m6A-dependent fashion, promoting its expression.
    • Macrophage Activation: THBS1 overexpression counteracted the metabolic and phenotypic suppression caused by IGF2BP1 knockdown, restoring M2 markers, glycolytic gene expression, and metabolic flux.
    • TLR4 Involvement: THBS1 interacts with TLR4, and TLR4 overexpression reversed the effects of THBS1 knockdown on M2 polarization and glycolytic metabolism, confirming the relevance of this axis.

    Collectively, these results delineate a pathway where the m6A reader IGF2BP1 promotes macrophage glycolytic metabolism and profibrotic activity by stabilizing THBS1 mRNA, activating TLR4-dependent signaling, and fostering the M2 phenotype. This mechanistic clarity spotlights potential molecular targets for therapeutic intervention in PF, especially where macrophage-driven processes drive pathology (reference).

    Comparison with Existing Internal Articles

    Several internal resources expand on the experimental and translational applications of macrophage colony stimulating factor (M-CSF) in disease modeling:

    Together, these resources contextualize the use of recombinant cytokines in dissecting macrophage-mediated mechanisms in fibrosis and provide practical details for experimental reproducibility.

    Limitations and Transferability

    While the study robustly establishes the IGF2BP1/THBS1/TLR4 axis in mouse models of PF, certain limitations merit consideration:

    • Species Specificity: The findings are based on murine models and primary cells; although human M-CSF is active in mice, mouse M-CSF is species-specific and direct extrapolation to human disease requires validation (product_spec).
    • In Vivo Complexity: The interplay of multiple immune and stromal cell types in the lung microenvironment is only partially recapitulated in the study’s in vitro and in vivo models.
    • Therapeutic Translation: While the IGF2BP1/THBS1/TLR4 axis represents a promising target, further work is needed to assess safety, efficacy, and specificity of interventions in clinical settings.

    Despite these limitations, the mechanistic insights provide a valuable framework for future translational research in fibrotic and inflammatory disease contexts.

    Research Support Resources

    To facilitate reproducible macrophage differentiation and polarization in studies of fibrotic signaling—such as those investigating the IGF2BP1/THBS1/TLR4 axis—researchers can employ Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021). This reagent, produced in a HEK293 system, offers validated potency for driving macrophage survival, proliferation, and differentiation in mouse models and supports experimental workflows requiring precise control of macrophage biology (product_spec). For protocol optimization and troubleshooting, internal articles such as the ones linked above provide actionable insights for integrating M-CSF into macrophage-mediated fibrosis and immune modulation research.